TYPE 2 DIABETES MELLITUS

✓ Medically ReviewedDISEASEID: MDBT0261🚨 TRIAGE: URGENTICD-10: E11

📖

Definition

CLINICAL DEFINITION

Type 2 diabetes mellitus is a chronic, progressive metabolic disorder characterised by hyperglycaemia resulting from a combination of insulin resistance and progressive pancreatic beta-cell dysfunction, leading to relative insulin deficiency. Diagnosis is established by accepted plasma glucose or glycated haemoglobin (A1C) criteria, including fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL), 2-hour plasma glucose ≥11.1 mmol/L (≥200 mg/dL) during a 75-g oral glucose tolerance test (OGTT), or A1C ≥6.5% (≥48 mmol/mol). In the absence of unequivocal hyperglycaemia or classic symptoms, confirmation by repeat testing is required.

IN PLAIN ENGLISH

Type 2 diabetes is a long-term condition in which the body does not use insulin properly and gradually loses the ability to produce enough insulin. This causes sugar (glucose) to build up in the blood. It matters because high blood sugar over time can damage the heart, blood vessels, kidneys, eyes, and nerves.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

Type 2 diabetes mellitus is NOT the same as type 1 diabetes mellitus, which results from autoimmune destruction of pancreatic beta cells and absolute insulin deficiency. Type 2 diabetes is also not synonymous with obesity alone, although obesity is a major risk factor, and it is not a single homogeneous disease but a heterogeneous group of metabolic disorders sharing the common phenotype of hyperglycaemia.

🔤

Word Breakdown

diabetes

=From Greek 'diabetes' meaning 'a siphon' or 'to pass through', referring to polyuria; 'mellitus' is Latin for 'honey-sweet'

Literal Meaning: A condition of excessive urine output, with the qualifying term 'mellitus' denoting honey-sweet urine, historically reflecting glycosuria

🏷️

Abbreviations

T2DM=Type 2 Diabetes Mellitus — the most widely used clinical abbreviation

T2D=Type 2 Diabetes — commonly used in research literature and guidelines

NIDDM=Non-Insulin-Dependent Diabetes Mellitus — historical term; no longer preferred because many patients with type 2 diabetes eventually require insulin

🔄

Synonyms & Variants

Type 2 Diabetes›Non-Insulin-Dependent Diabetes Mellitus›Adult-Onset Diabetes Mellitus›

🎯

Category-Specific Context

Type 2 diabetes mellitus is classified as a Disease because it is a defined pathological condition with recognised diagnostic criteria (ADA 2026 plasma glucose or A1C thresholds). It exists on a spectrum from prediabetes (impaired fasting glucose or impaired glucose tolerance) through established diabetes to complicated diabetes with microvascular and macrovascular disease. The category encompasses heterogeneous phenotypes, including obesity-associated, lean, and early-onset forms, and its clinical management is structured around glycaemic control and cardiorenal risk reduction.

🏥

Clinical Context & Usage

CLINICAL SETTINGS

General Practice / Primary CareEndocrinology Outpatient ClinicGeneral Medicine WardDiabetes Specialist Nurse ClinicCardiology Outpatient ClinicNephrology Outpatient ClinicOphthalmology Screening ClinicEmergency Department

USAGE & DOCUMENTATION NOTES

In clinical documentation, the term is commonly abbreviated as T2DM and recorded with the current HbA1c, most recent renal function, and presence or absence of complications. Ward rounds and referral letters often specify the therapeutic regimen (e.g., 'metformin 1 g BD plus empagliflozin 10 mg OD') and any cardiorenal indications. Screening notes document retinal screening status, foot examination findings, and urine albumin-to-creatinine ratio. When insulin is used, the type and total daily dose are recorded, and the historical terms 'controlled' and 'uncontrolled' are no longer used in ICD-10 coding, having been replaced by descriptors of hyperglycaemia and complication status.

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

Type 2 diabetes mellitus arises from the interaction of genetic susceptibility and environmental factors, principally chronic positive energy balance and visceral adiposity. Insulin resistance develops in skeletal muscle, liver, and adipose tissue, impairing insulin-stimulated glucose uptake and promoting hepatic gluconeogenesis. Initially, pancreatic beta cells compensate by increasing insulin secretion, maintaining near-normal glucose levels. Over time, progressive beta-cell dysfunction and loss of beta-cell mass occur, driven by glucotoxicity, lipotoxicity, and chronic low-grade inflammation, leading to relative insulin deficiency and sustained hyperglycaemia. Chronic hyperglycaemia causes microvascular damage through advanced glycation end-products, activation of the polyol pathway, and protein kinase C activation, and macrovascular damage through accelerated atherosclerosis, endothelial dysfunction, and a prothrombotic state. The resulting clinical phenotype includes hyperglycaemia, dyslipidaemia, hypertension, and a markedly increased risk of atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, retinopathy, and neuropathy.

PRIMARY CAUSES

Obesity and central adiposity

Excess visceral adipose tissue releases free fatty acids and adipokines that impair insulin signalling in muscle and liver, while ectopic fat deposition in pancreas and liver contributes to beta-cell dysfunction and hepatic insulin resistance.

Genetic predisposition

Multiple common genetic variants influence beta-cell function, insulin sensitivity, and adiposity; family history and certain ethnic backgrounds (e.g., South Asian, Hispanic, Indigenous) substantially increase susceptibility.

Physical inactivity

Reduced skeletal muscle glucose uptake and decreased insulin sensitivity; sedentary behaviour independently contributes to weight gain and metabolic dysfunction.

Unhealthy diet

High energy density, refined carbohydrate, and sugar-sweetened beverage intake promote weight gain, hepatic steatosis, and postprandial hyperglycaemia, accelerating insulin resistance and beta-cell demand.

Ageing

Age-related decline in beta-cell function and mass, sarcopenia, and increased visceral adiposity contribute to reduced glucose tolerance.

Gestational diabetes mellitus history

Pregnancy-related insulin resistance unmasked underlying beta-cell dysfunction; a history of gestational diabetes confers a markedly increased lifetime risk of progression to type 2 diabetes.

Polycystic ovary syndrome (PCOS)

Insulin resistance and compensatory hyperinsulinaemia contribute to androgen excess and metabolic dysfunction, increasing the risk of impaired glucose tolerance and type 2 diabetes.

💊

Drug-Induced Causes

💊 Glucocorticoids (prednisolone, dexamethasone, hydrocortisone) ↗

Mechanism: Increase hepatic gluconeogenesis, reduce peripheral insulin sensitivity, and impair beta-cell function; risk is dose- and duration-dependent.

→ Use the lowest effective dose for the shortest duration; monitor glucose during treatment; consider steroid-sparing agents or alternative routes where feasible; if hyperglycaemia develops, treat according to standard diabetes pathways, recognising that glucocorticoid-induced hyperglycaemia often requires basal insulin or specific agent selection.

💊 Atypical antipsychotics (clozapine, olanzapine, quetiapine) ↗

Mechanism: Cause weight gain, insulin resistance, and direct effects on beta-cell function; olanzapine and clozapine carry the highest metabolic risk.

→ Baseline and periodic monitoring of weight, fasting glucose, and lipids; prefer lower-metabolic-risk antipsychotics where clinically appropriate; if hyperglycaemia develops, manage as for type 2 diabetes with attention to medication adherence and mental health context.

💊 Thiazide diuretics (hydrochlorothiazide, bendroflumethiazide, indapamide) ↗

Mechanism: Induce hypokalaemia and reduce insulin secretion; may also increase insulin resistance.

→ Monitor potassium and glucose; use the lowest effective dose; consider alternative antihypertensives if glycaemic deterioration occurs; the cardiovascular benefits of thiazides generally outweigh the modest hyperglycaemic risk in most patients.

💊 Statins (atorvastatin, rosuvastatin, simvastatin) ↗

Mechanism: Small increase in incident diabetes risk, possibly through effects on insulin sensitivity and beta-cell function; the mechanism is not fully established.

→ Do not discontinue statins solely because of hyperglycaemia; monitor glucose as part of routine care; the cardiovascular benefit of statins generally outweighs the small diabetogenic risk.

💊 Beta-blockers (especially non-vasodilating agents) ↗

Mechanism: May reduce insulin sensitivity and mask hypoglycaemia symptoms; effects vary by agent.

→ Monitor glucose when initiating or titrating; prefer cardioselective or vasodilating beta-blockers where appropriate; do not withhold indicated beta-blockade solely for glycaemic concerns.

💊 Antiretroviral therapy (protease inhibitors, some NRTIs) ↗

Mechanism: Protease inhibitors cause insulin resistance and dyslipidaemia; some NRTIs affect mitochondrial function and adipose tissue metabolism.

→ Monitor glucose and lipids in people living with HIV on antiretroviral therapy; consider switching to metabolically neutral regimens in consultation with HIV specialists if hyperglycaemia develops.

🌍

Epidemiology

Prevalence:Globally, an estimated 589 million adults aged 20–79 years were living with diabetes in 2024, and type 2 diabetes accounts for over 90% of all diabetes cases. The global adult diabetes prevalence is approximately 11%, with 3 in 4 adults with diabetes living in low- and middle-income countries. An estimated 1 in 8 adults are at high risk of developing type 2 diabetes. In North America, diabetes prevalence is approximately 15%, and in Africa approximately 4.2%, with more than 50% of cases undiagnosed in that region.

Age Group:Historically most common in adults over 40–45 years, but increasingly diagnosed in younger adults, adolescents, and children, particularly in populations with high obesity prevalence and in Indigenous and South Asian communities. The incidence in youth and young adults is rising globally.

Sex Predilection:Equal

Geographic Distribution:Type 2 diabetes is a global pandemic, but prevalence varies substantially by region and ethnicity. The highest age-adjusted prevalence is observed in North America and the Middle East and North Africa, while the largest absolute numbers of affected adults reside in China and India. South Asian, Hispanic, Indigenous, and Pacific Islander populations experience earlier onset and more aggressive cardiorenal complications at lower body mass index thresholds compared with European-ancestry populations. Urbanisation, dietary transition, and reduced physical activity drive regional differences.

Red Flags & Triage ★

TRIAGE LEVEL

🚨 URGENT

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

A patient presenting with polyuria, polydipsia, and weight loss who has profound hyperglycaemia and ketonaemia should be evaluated urgently for diabetic ketoacidosis, even if the underlying diabetes type is not yet classified; type 2 diabetes can present with DKA, particularly in certain ethnic groups and with SGLT2 inhibitor use.
New-onset diabetes in an older adult with unintentional weight loss or abdominal pain should prompt consideration of pancreatic cancer or other secondary causes; a low threshold for abdominal imaging is warranted when clinical features are atypical.
Severe hyperglycaemia with dehydration, altered mental status, and marked hyperosmolality in an older adult should raise concern for hyperglycaemic hyperosmolar state (HHS), which carries high mortality and requires immediate fluid and insulin management in a monitored setting.

URGENT EVALUATION TRIGGERS

Blood glucose >30 mmol/L (>540 mg/dL) or hyperglycaemic symptoms with dehydration, vomiting, or altered consciousness — evaluate immediately for hyperglycaemic crisis (DKA or HHS).
Ketonaemia (blood beta-hydroxybutyrate ≥3.0 mmol/L) or ketonuria with hyperglycaemia — urgent assessment for diabetic ketoacidosis.
Rapidly progressive foot ulceration, cellulitis, or signs of limb ischaemia in a person with diabetes — same-day assessment by a multidisciplinary foot service or emergency department.
Chest pain, new dyspnoea, or neurological deficit in a person with type 2 diabetes — urgent evaluation for acute coronary syndrome or stroke, as presentation may be atypical.

Contraindications & Precautions

SPECIAL PRECAUTIONS

Assess renal function before and during use of metformin and SGLT2 inhibitors; metformin is contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m²)
and SGLT2 inhibitors require dose adjustment or avoidance at low eGFR depending on the agent.
Screen for and manage sick-day rules with SGLT2 inhibitors and metformin; temporary interruption is advised during acute illness
dehydration
or before surgery to reduce the risk of euglycaemic diabetic ketoacidosis and lactic acidosis.
Individualise glycaemic targets
particularly in older adults
those with frailty
cognitive impairment
or limited life expectancy
to avoid hypoglycaemia; less stringent A1C targets may be appropriate.
Screen for diabetic retinopathy before initiating rapid glycaemic improvement and during pregnancy; rapid improvement in chronic hyperglycaemia can transiently worsen retinopathy.
Assess for contraindications and precautions before prescribing GLP-1 receptor agonists or tirzepatide
including a history of medullary thyroid carcinoma
multiple endocrine neoplasia type 2
pancreatitis
or severe gastroparesis.

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Diabetic retinopathy — microvascular damage to retinal capillaries
leading to macular oedema
proliferative retinopathy
and vision loss
Diabetic kidney disease — glomerular hyperfiltration and albuminuria progressing to chronic kidney disease and end-stage renal disease
Diabetic peripheral neuropathy — distal symmetric sensory and motor nerve damage
causing pain
numbness
and foot ulceration
Atherosclerotic cardiovascular disease — accelerated coronary
cerebrovascular
and peripheral arterial disease
including myocardial infarction and stroke
Heart failure — increased risk independently associated with diabetes
often with preserved ejection fraction
Diabetic foot ulceration and lower-limb amputation — resulting from neuropathy
peripheral arterial disease
and infection
Hyperglycaemic hyperosmolar state (HHS) — severe hyperglycaemia
hyperosmolality
and dehydration
typically in older adults with type 2 diabetes
Diabetic ketoacidosis (DKA) — can occur in type 2 diabetes
particularly in the context of severe illness
certain drug therapies (e.g.
SGLT2 inhibitors)
or early-onset disease

🔀

Confused With (LASA & DDx) ★

LEXICAL (LASA) — SIMILAR NAMES

Diabetes Insipidus

Shares the word 'diabetes' but denotes a disorder of antidiuretic hormone (ADH) secretion or action, causing polyuria without glycosuria; confusion can lead to inappropriate glucose-focused management.

Type 1 Diabetes Mellitus

Distinguished by autoimmune beta-cell destruction and absolute insulin deficiency; misclassification can delay appropriate insulin therapy and lead to diabetic ketoacidosis.

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Type 1 Diabetes Mellitus

Key Distinguishing Feature: Younger age at onset, leaner body habitus, positive pancreatic autoantibodies (e.g., GAD65, IA-2), and a tendency to ketoacidosis; C-peptide is typically low.

Latent Autoimmune Diabetes in Adults (LADA)

Key Distinguishing Feature: Adult-onset diabetes with positive pancreatic autoantibodies and slower progression to insulin dependence than classic type 1 diabetes; initially may resemble type 2 diabetes.

Monogenic Diabetes (e.g., MODY)

Key Distinguishing Feature: Young onset (often <25 years), strong family history, absence of obesity and autoantibodies, and preserved endogenous insulin secretion; genetic testing confirms the diagnosis.

Drug-Induced Hyperglycaemia or Diabetes

Key Distinguishing Feature: Temporal relationship with a culprit medication (e.g., glucocorticoid, antipsychotic, statin), improvement after dose reduction or discontinuation, and absence of typical metabolic syndrome features.

Secondary Diabetes due to Pancreatic Disease (e.g., Chronic Pancreatitis, Pancreatic Cancer)

Key Distinguishing Feature: History of pancreatic disease, malabsorption, or pancreatic surgery; imaging evidence of pancreatic pathology; may require insulin early.

💎

Clinical Pearls

💎

Type 2 diabetes is a progressive disease: the UKPDS and subsequent trials demonstrated that beta-cell function declines over time, so most patients eventually require treatment intensification. Early combination therapy with metformin and an SGLT2 inhibitor is now recommended for many patients, shifting away from prolonged stepwise monotherapy.

💎

The presence of obesity does not exclude type 1 diabetes or monogenic diabetes. When clinical features are atypical (young age, lean body habitus, rapid progression to insulin requirement, or strong family history), check pancreatic autoantibodies and consider C-peptide and genetic testing.

💎

Cardiorenal protection should be a primary treatment goal alongside glycaemic control. SGLT2 inhibitors and GLP-1 receptor agonists reduce major adverse cardiovascular events, heart failure hospitalisation, and progression of chronic kidney disease, and these benefits are at least partly independent of glycaemic lowering.

💎

Sulfonylureas and insulin remain effective but carry a higher risk of hypoglycaemia, particularly in older adults and those with renal impairment. When these agents are used, set individualised glycaemic targets and provide structured hypoglycaemia education.

💎

The term 'non-insulin-dependent diabetes mellitus' (NIDDM) is obsolete and misleading. Many people with type 2 diabetes eventually require insulin, and classification should be based on pathophysiology and autoantibody status rather than on historical labels.

📝

Example Usage & SOAP

CLINICAL SENTENCE

""58-year-old man with a 6-year history of type 2 diabetes mellitus on metformin 1 g BD and empagliflozin 10 mg OD, with an HbA1c of 8.1% (65 mmol/mol), eGFR 62 mL/min/1.73 m², and UACR 45 mg/mmol, referred for optimisation of cardiorenal risk factor management.""

IN A SOAP NOTE

S: 58-year-old man reports increased fatigue and nocturia over 3 months. He has a known history of type 2 diabetes mellitus diagnosed 6 years ago, hypertension, and obesity (BMI 32 kg/m²). Current medications: metformin 1 g BD, empagliflozin 10 mg OD, ramipril 5 mg OD, atorvastatin 20 mg OD. O: BP 148/86 mmHg, weight 98 kg, BMI 32.4 kg/m². HbA1c 8.1% (65 mmol/mol). eGFR 62 mL/min/1.73 m². UACR 45 mg/mmol. Foot examination: monofilament intact, pedal pulses present. A: Type 2 diabetes mellitus with suboptimal glycaemic control and moderately increased albuminuria; hypertension above target. P: Continue metformin and empagliflozin. Add semaglutide 0.25 mg weekly, titrating to 0.5 mg after 4 weeks, for glycaemic and cardiorenal benefit. Reinforce lifestyle measures. Repeat UACR and eGFR in 3 months. Refer to diabetes specialist nurse for structured education.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential for a newly diagnosed adult with hyperglycaemia: (1) Type 2 diabetes mellitus — supported by age, obesity, metabolic syndrome features, and absence of autoantibodies. (2) Type 1 diabetes mellitus — consider if young, lean, ketosis-prone, or autoantibody-positive. (3) Latent autoimmune diabetes in adults (LADA) — consider if adult-onset but autoantibody-positive with slower insulin requirement. (4) Monogenic diabetes (MODY) — consider if young onset, strong family history, and preserved C-peptide. (5) Drug-induced diabetes — review glucocorticoid, antipsychotic, statin, and thiazide exposure. The clinical context, autoantibody testing, C-peptide, and sometimes genetic testing guide classification.

📈

Prognosis

SHORT-TERM OUTCOME

With contemporary management, most people with type 2 diabetes can achieve glycaemic targets and reduce short-term hyperglycaemic symptoms. However, within three years of diagnosis, a substantial proportion develop microvascular or macrovascular complications; one population-based cohort reported that 36% developed complications and 4% died within three years of diagnosis. Short-term prognosis is strongly influenced by baseline glycaemic control, blood pressure, renal function, and the presence of cardiovascular disease.

LONG-TERM PROGNOSIS

Long-term prognosis is heterogeneous. Early and sustained glycaemic control, together with blood pressure and lipid management, substantially reduces the risk of microvascular complications and cardiovascular death. People with type 2 diabetes have an approximately twofold to fourfold increased risk of cardiovascular events compared with the general population, and diabetes is responsible for over 3.4 million deaths annually worldwide. The development of microvascular disease further amplifies cardiovascular and mortality risk, and heart failure risk is approximately 84% higher in people with type 2 diabetes than in those without.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

E11

LITERATURE CITATIONS & GUIDELINES

[1]American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27–S49. doi:10.2337/dc26-S002

[2]International Diabetes Federation. IDF Diabetes Atlas, 11th edition. 2025. https://diabetesatlas.org

[3]National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline NG28. Updated 2026. https://www.nice.org.uk/guidance/ng28

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.